GSK Trading Volume Surges 76.74% to 326 Million Shares, Ranks 321st Amid Regulatory Challenges

On July 15, 2025, GSK's trading volume reached 326 million, marking a 76.74% increase from the previous day, ranking 321st in the day's stock market. GSK's stock price fell by 1.23%.

GSK's blood cancer therapy has been flagged by FDA reviewers for potential eye risks. This development comes as the FDA has also ended the import screening exemption for low-value goods, adding to the regulatory challenges faced by the pharmaceutical company. The FDA's concerns over eye safety risks could impact GSK's ongoing clinical trials and market approval processes for its blood cancer treatments.

GSK's stock price decline may be attributed to the increased scrutiny from regulatory bodies, which could potentially delay the approval of new treatments or require additional safety measures. Investors are likely monitoring these developments closely, as regulatory setbacks can significantly affect a pharmaceutical company's market position and financial performance.